Diabetes-related supplies include insulin pumps and supplies (eg, pump unit, infusion sets), continuous glucose monitors and supplies (eg, sensors, transmitters, and receivers), glucometers and supplies (eg, meter, lancets, glucose strips), urine testing strips, blood ketone tests, needles, and syringes. Data from IBM Watson Health.3
eAppendix 1. Methodology for Identifying Insulin Claims
eAppendix 2. CPT/HCPCS Codes for Diabetes-Related Supplies
eAppendix 3. National Drug Codes for Diabetes-Related Supplies
eAppendix 4. Anti-Diabetes Medications
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chua K, Lee JM, Conti RM. Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes. JAMA Intern Med. 2020;180(7):1012–1014. doi:10.1001/jamainternmed.2020.1308
Concern about high out-of-pocket spending for insulin has prompted states, payers, and pharmacy benefit managers to limit cost-sharing in the US.1,2 In addition to insulin, patients with type 1 diabetes might have out-of-pocket expenses for other care, such as diabetes-related supplies. Using national 2018 claims data, we estimated out-of-pocket spending for insulin and other health care services for privately insured patients with type 1 diabetes.
We analyzed 2018 data from the IBM MarketScan Commercial Database,3 which included patients with employer-sponsored coverage from medium to large firms. We included patients aged 1 to 64 years with continuous enrollment throughout 2018, 1 or more type 1 diabetes diagnosis code in 2017 (to limit the analysis to established patients), and 1 or more insulin claim in 2018. Because the data used were deidentified, the institutional review board of the University of Michigan Medical School did not regulate this study as human participant research; informed consent was not required.
We assigned inpatient, outpatient, and pharmacy claims in 2018 to 4 categories: (1) insulin, (2) diabetes-related supplies (eg, insulin pumps, glucometers), (3) other type 1 diabetes–related services (medications such as sulfonylureas and inpatient/outpatient claims with a type 1 diabetes diagnosis code), and (4) all other services not assigned to the first 3 categories (eg, visits for viral illness) (eAppendixes 1-4 in the Supplement). Based on whether patients had 1 or more claim for insulin pumps or associated supplies, and whether patients had 1 or more claim for continuous glucose monitors or associated supplies, we classified patients as using pumps only, continuous glucose monitors only, both, or neither.
For each category, we calculated the mean (SD) and median annual out-of-pocket spending. We calculated the proportion of annual overall out-of-pocket spending accounted for by insulin. We also calculated out-of-pocket spending for diabetes-related supplies according to use of insulin pumps and continuous glucose monitors.
In subgroup analyses, we stratified by age (children aged 1 to 17 years vs adults aged 18 years or older) and enrollment in a high-deductible health plan, defined as qualified high-deductible health plans with statutorily defined minimum deductibles of US $1350 for individual and US $2700 for family coverage in 2018 or consumer-driven health plans that typically couple high deductibles with health reimbursement arrangement accounts.4
The 65 192 patients who met the inclusion criteria had a mean (SD) age of 40.8 (16.5) years and included 7842 children (12.0%), 30 133 women (46.2%), and 14 680 individuals (22.5%) enrolled in high-deductible health plans. Overall, 37 042 patients (56.8%) used insulin pumps, continuous glucose monitors, or both.
The use of diabetes technologies and annual out-of-pocket spending are shown in the Table. Mean (SD) annual out-of-pocket spending for insulin was lower ($435 [$544]) than spending for diabetes-related supplies ($490 [$785]). Mean (SD) annual overall out-of-pocket spending was $2414 ($3531); for 5191 patients (8.0%), this spending exceeded $5000. Insulin accounted for 18.0% of overall out-of-pocket spending. Mean (SD) annual out-of-pocket spending for diabetes-related supplies varied among patients who used insulin pumps only ($562 [$626]), continuous glucose monitors only ($472 [$625]), both ($1037 [$1039]), or neither ($79 [$175]).
Compared with adults, children had higher use of diabetes technologies and higher out-of-pocket spending for diabetes-related supplies (Table). Among children, out-of-pocket spending for diabetes-related supplies ($823) was higher than for insulin ($497) (Figure). Among adults, out-of-pocket spending for diabetes-related supplies ($445) and insulin ($427) were similar. Patients enrolled in high-deductible health plans had higher out-of-pocket spending in each category than patients enrolled in other plans (Table).
In a national sample of privately insured patients with type 1 diabetes, mean out-of-pocket spending for all care was nearly $2500 in 2018. For 8% of patients, this spending exceeded $5000. Insulin accounted for 18% of all out-of-pocket spending and less out-of-pocket spending than diabetes-related supplies. Findings suggest that substantial out-of-pocket burden may remain for patients with type 1 diabetes even if insulin cost-sharing is limited. Government officials and insurers should consider improving coverage for all type 1 diabetes–related services, following the approach of a 2019 rule allowing qualified high-deductible health plans to cover services such as insulin and glucometers before deductibles are met.5
This study has limitations. We did not study patients covered by Medicare or Medicaid or those without insurance. The database included patients who received insurance from medium to large firms,3 which typically offer plans with lower deductibles compared with plans offered by small firms.6 Consequently, findings may underestimate out-of-pocket spending for patients with type 1 diabetes who receive insurance from small firms.
Accepted for Publication: March 4, 2020.
Published Online: June 1, 2020. doi:10.1001/jamainternmed.2020.1308
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Chua K-P et al. JAMA Internal Medicine.
Corresponding Author: Kao-Ping Chua, MD, PhD, Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, 300 N Ingalls St, SPC 5456, Room 6E18, Ann Arbor, MI 48109 (email@example.com).
Author Contributions: Dr Chua had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Chua, Conti.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Chua, Conti.
Administrative, technical, or material support: Lee, Conti.
Conflict of Interest Disclosures: Dr Lee reported serving as a consultant for the Type 1 Diabetes Exchange, serving on the medical advisory board of GoodRx, and receiving grant funding from Lenovo. No other disclosures were reported.
Funding/Support: Dr Chua was supported by a career development award 1K08DA048110-01 from the National Institute on Drug Abuse. Dr Lee was supported by grants 1-R01-HD-074559-01-A1 and UH3HD087979 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, by the JDRF (formerly Juvenile Diabetes Research Foundation), and by the M-Diabetes Center of Excellence at the University of Michigan.
Additional Contributions: Technical assistance for this project was provided by the Michigan Center for Diabetes Translational Research (grant P30DK092926 from the National Institute of Diabetes and Digestive and Kidney Diseases). The organization received no payment for its contribution.